Thank you for the submission of your research manuscript to our editorial office. First of all I would like to express my apologies for the unusual delay in getting back to you with a decision on your study. I have now had the opportunity to carefully read it and I have also discussed it with the other members of our editorial team and with an additional advisor of relevant expertise in the field. I am afraid that the outcome of these discussions is not a positive one, as we all agree that the manuscript is not well suited for publication in EMBO reports.
Thank you for the submission of your research manuscript to our editorial office. First of all I would like to express my apologies for the unusual delay in getting back to you with a decision on your study. I have now had the opportunity to carefully read it and I have also discussed it with the other members of our editorial team and with an additional advisor of relevant expertise in the field. I am afraid that the outcome of these discussions is not a positive one, as we all agree that the manuscript is not well suited for publication in EMBO reports.
We acknowledge that you have provided evidence that miR-10b supports the self-renewal of breast cancer stem cells by inhibiting the expression of PTEN Both we and our advisor, who carefully read your manuscript, appreciate the potential interest of these findings. However, our advisor also considers the study to be too preliminary to warrant consideration for publication here. S/he raised several technical and experimental concerns that in his/her opinion prevented the study from being fully conclusive. I am pasting an excerpt of our advisor's comments at the bottom of this email.
Based on these considerations our advisor did not recommend in-depth review of the study at this point and we have decided to return it to you so that you can seek publication elsewhere without further delays. We would, however be open to a submission of a related study in the future that addressed the criticisms pointed out by our advisor. I would like to stress, though, that such a study would be treated as a new submission, also with regard to the novelty of the findings at the time of submission.
Thank you very much for the submission of your research manuscript to our editorial office and for your patience while we were waiting to hear back from the referees. We have just now received the full set of reviews on your manuscript.
As the detailed reports are pasted below I will only repeat the main points here. All reviewers agree on the potential interest of the findings and, in principle, support publication of it in EMBO reports once their concerns have been addressed. All reviewers agree that additional evidence is needed to prove that PTEN is a direct target of miR-10b and provide suggestions on how to achieve this (e.g. through rescue experiments, mutational analysis of the miR-10b binding site in the PTEN promoter and the analysis of the effects of miR-10b on endogenous target genes). Referee 1 feels that the soft agar colony formation assay is not sufficient to prove stemness of the cells and upon further discussions, referee 3 agrees with this concern and suggests to perform additional tests, for example FACS sorting by surface markers like CD24/CD133, ALDH enzymatic tests and Hoechst dye exclusion. Both reviewers 2 and 3 feel that the main experiments should also be performed in a basal cell line. Referee 3 states that an explanation for the rather high statistical variability and/or mild effects of some of the experiments should be provided. In this regard and if you not have done so yet, please make sure to clearly state for all experiments how many independent times (biological, not technical replicates) they have been repeated and which statistical tests have been performed in each case. In addition to these specific points, the reviewers also point out other instances in which in which the study could be improved, but since they are rather clearly stated in their reports and are mostly minor, I would refrain from repeating them here.
Given the potential interest of your findings, I would like to give you the opportunity to revise your manuscript, with the understanding that the main concerns of the referees should be addressed. ************************* REFEREE REPORTS Referee #1:
In this manuscript, the authors report that miR-10b expression in breast cancer stem cells (CSCs) promotes CSC properties by targeting PTEN. This is an interesting finding. I have the following criticisms:
1. The authors state that "we found 142 deregulated miRNAs (119 up-regulated and 33 downregulated) in MCF-7 luminal CSC cells and 9 deregulated miRNAs (5 up-regulated and 4 downregulated) in MDA-MB-231 basal CSCs (data not shown)". These data should be presented.
2. In several cases the authors used soft agar colony formation assays to determine the effect on breast CSCs. However, this assay alone is not a CSC assay, since it gauges anchorage-independent growth of proliferating cancer cells (not necessarily CSCs).
3. Figure 2C : the authors used in vivo limiting dilution analysis to determine whether miR-10b regulates CSCs. The frequency of CSCs should be calculated from this analysis. Also, the authors used 3 doses (50,000, 100,000 and 200,000 cells) for injection, but the numbers on the X axis only show 10,000 -50,000 cells.
4. I cannot find PTEN in the list of human miR-10b targets predicted by TargetScan: http://targetscan.org/cgibin/targetscan/vert_61/targetscan.cgi?species=Human&gid=&mir_sc=&mir_c=&mir_nc=&mirg=hs a-miR-10b
Can the authors explain how they used TargetScan or other computational programs to identify PTEN as a predicted human miR-10b target?
5. Figure 3D : the difference in PTEN levels looks minor.
6. The evidence that PTEN mediates miR-10b's function is weak. The authors should determine whether PTEN expression can reverse the overexpression effect of miR-10b, and whether knockdown of PTEN can reverse the loss-of-function effect of miR-10b in breast CSCs.
Referee #2:
Comments:
In this manuscript, the authors report the relevant finding that miR-10b can suppress PTEN expression in breast cancer stem cells.
It has been previously reported that PTEN can be repressed by miR-10b in glioblastoma, and that this regulation correlates with an increase in cell motility and self-renewal.
Currently, however, there is no reported evidence that miR-10b can act as a PTEN regulator in breast cancer, and the authors provide necessary experimental data in support of this tenet. The results described in the manuscript will be useful to the molecular biology community towards the exploration of potential therapeutic applications, as well as to start a more thorough investigation into understanding the consequence of this mode of PTEN regulation.
While the role of miR-10b in breast cancer is well supported by the data presented in the manuscript, it would be important to provide additional data obtained in a basal cell line, as this part is poorly developed as compared to the part carried out in the luminal cell line. The following points should also be addressed in a revised manuscript:
Major Points 1-A table with the expression profiles of the 353 miRNAs that the authors have analyzed should be presented. Additionally, the authors need to explain and provide data to support their decision to use miR-10b. In the manuscript the authors only state: "We detected numerous deregulated miRNAs" and "We demonstrated that this miRNA is up-regulated in CSCs that are isolated from both luminal and basal breast cancer cell lines". The authors should provide the rationale justifying the choice to subject miR-10b to further characterization.
2-The statement, "We then selected 3 cell lines with high miR-10b expression and transiently transfected specific anti-miRs moieties" should be expanded on by the authors to specify which cell lines were used, as this data is not currently included. The clarification is important because the authors describe a different, Vimentin expression for MCF7 compared with MB-231, but there is no mention or data regarding the third of "3 cell lines".
3-In regards to the mammospheres assay in Fig. S2 B, the authors should explore if E-cadherin expression, a well-known marker for mammosphere formation, changes by using IF staining for this protein. It would be a relevant finding if the difference in mammosphere formation and morphology between miR-Ctl-OE and miR-10b-OE was accompanied by a difference in E-cadherin levels ( 5-Importantly, to determine a direct role for PTEN the authors should also carry out add back/replacement controls experiments performed by knocking down the endogenous PTEN, and next re-expressing a PTEN with a mutated MRE site for miR-10b. These controls are missing and very much needed.
Referee #3:
In this manuscript the authors identified a role of the metastamiR miR-10b in regulation of tumor stem cell characteristics. In breast cancer cell lines they found that CSC-enriched populations show increased expression of miR-10b. Based on in silico prediction tools PTEN and PIK3CA 3'UTRs were suggested as putative miR-10b targets. By knockdown and overexpression experiments the authors analyzed these targets and found that PTEN is a target of miR-10b. Consequently, PI3K signaling is activated (or derepressed) which is crucial in providing tumor stemness.
The role of individual microRNAs that are upregulated in highly invasive and metastasizing tumors is still elusive and a better understanding is of particular interest and of great importance how microRNAs help to sustain cancer stem cells. As in this scenario very important genes are involved that are well-known for their role in tumorigenesis and CSC biology further raises the impact of the findings. However, to demonstrate the importance of the suggested link of miR-10b, PTEN, PI3K and stemness in molecular terms conclusively, some important experiments need to be added to the more preliminary data presented in the manuscript. One major criticism is that the data, especially in important experiments, display either high statistical variability or only marginal effects, which challenges the biological relevance. Moreover, the way how data are presented makes it often difficult to extract the main results of the experiment. Below, I listed my major concerns about the manuscript in detail:
1. To address the role of miR-10b in CSCs the author very smartly analyzed CSC-enriched populations of luminal and basal breast cancer lines. However, they only used one cell type (luminal, MCF7) consistently for all experiments and added in some experiments extra cell lines. The main experiments should be done also with MDA-MB-231 cells and the other cell lines should be introduced and characterized better (miR-10b, PTEN, p-AKT expression levels), including a similar cell sorting to enrich for CSCs.
2. The authors suggest a mechanism in which miR-10b elevation results in decreased PTEN levels which in turn leads to increased PI3K signaling, represented by higher p-AKT levels. This is verified only by knockdown of PTEN in MCF7 cells. To show that this is a cascade of events, PTEN knockdown should be carried out after miR-10b overexpression and knockdown. In line of the hypothesis, PTEN overexpression should compensate for miR-10b overexpression.
3. In general, the qPCR data show a huge variability, sometimes up to 100-fold ( Figs 1F, 2D) . What is the reason for that?
4. Mammosphere/colony forming assay: It is not clearly described whether these are individual assays. A mammosphere assay is not described in the Materials and Methods section. It is inconsistent that sometimes colonies/spheres were counted and in other experiments dissociated and counted in single cell amounts. 7. Fig 3B: the effect of miR-10b was shown by luciferase reporter assays using different 3'UTRs. In addition, the effects of miR-10b on endogenous transcripts and protein should be evaluated 8. Minor points: 1. Page 7: "We then selected 3 cell lines with high miR-10b expression and transiently transfected specific anti-miRs moieties." The analysis of different cell lines with respect to their miR-10b expression level is not shown. This is important to verify which cell lines have high and low miR10b expression levels, also with respect to the changes in miR-10b levels in the CSC-enriched fractions. Response to Reviewers Referee #1:
The data were added to the main manuscript as a heatmap in Figure 1 and Dataset EV1.
We agree, so we moved the soft agar assays to Fig. EV2 and modified the text accordingly. We also added additional experiments, such as serial mammosphere assays ( Fig. 1 and 2 ), ALDH assays ( Fig. EV2 ) and in vivo experiments (Fig. 2) , and kept the dilution assays ( Fig. 1 and 2 ).
We are sorry for the mistake. We corrected the Fig and text and calculated the CSCs frequency from this.
I cannot find PTEN in the list of human miR-10b targets predicted by TargetScan:
We are unsure of the reasons for the change in the way that the search engine of TargetScan displays results in the new version. The database portrays now only evolutionary conserved sites of specific groups, even when there is statistical support for a site (miR10b is conserved among vertebrates and not only in mammals, which are now displayed in the search engine). Going in the other way (searching for PTEN and looking for miRNAs sites) shows that the prediction is valid, showing unequivocally the miR-10b site. Please see the included pdf showing more information and the support for other databases (mir10b_databases.pdf).
We performed densitometric analyses to show the reproducibility of our assays. microRNAs regulation of mRNAs are generally subtle.
We included various additional experiments for this. In the first one, we knocked down PTEN in SKBR-3 overexpressing miR10b cells (Fig. 3G ) and in T-47D in which miR-10b was knocked down, and measured stem cell markers and mammospheres, respectively. Additionally, we overexpressed either PTEN or PTEN with a mutated version of miR-10b binding site in cells overexpressing miR-10b to show that PTEN was responsible for miR-10b effect and that this was dependent on the miR-10b MRE (Fig. 3H ).
Referee #2:
We added a more complete heatmap of the common deregulated miRNAs in Fig. 1 2-The statement, "We then selected 3 cell lines with high miR-10b expression and transiently transfected specific anti-miRs moieties" should be expanded on by the authors to specify which cell lines were used, as this data is not currently included. The clarification is important because the authors describe a different, Vimentin expression for MCF7 compared with MB-231, but there is no mention or data regarding the third of "3 cell lines". We corrected the text (page 7) specifying which cell lines were used and added their miR-10b expression levels (Fig. EV3C) 3-In regards to the mammospheres assay in Fig. S2 B, the authors should explore if E-cadherin expression, a well-known marker for mammosphere formation, changes by using IF staining for this protein.
It would be a relevant finding if the difference in mammosphere formation and morphology between miR-Ctl-OE and miR-10b-OE was accompanied by a difference in E-cadherin levels (Fig.  S2 B) .
We concur that this could be a very interesting experiment. We added fig EV2G, in which we show, using immunohistochemistry, that miR-10b overexpression in SKBR-3 cells increased the expression of E-cadherin. Fig. S2 one finds a legend for the Panel C "gene expression profiles contrasting the expression of stemness and EMT marker..." but there is no Panel C. The authors must fix this discrepancy.
4-In
The discrepancy was fixed.
5-Importantly, to determine a direct role for PTEN the authors should also carry out add back/replacement controls experiments performed by knocking down the endogenous PTEN, and next re-expressing a PTEN with a mutated MRE site for miR-10b. These controls are missing and very much needed.
Referee #3:
1. To address the role of miR-10b in CSCs the author very smartly analyzed CSC-enriched populations of luminal and basal breast cancer lines. However, they only used one cell type (luminal, MCF7) consistently for all experiments and added in some experiments extra cell lines.
The main experiments should be done also with MDA-MB-231 cells and the other cell lines should be introduced and characterized better (miR-10b, PTEN, p-AKT expression levels), including a similar cell sorting to enrich for CSCs.
We added experiments with MDA-MB-231 cells (Fig. 1, 2) . To further support the data, we also provide experiments in the HER2 positive SKBR3 cell line (including in vivo analyses, Fig.  2C ) and T47D cells (Fig. 3B) .
We performed the experiments requested (Fig. 3H) , which shows that re-expressing PTEN eliminated the increase in stem cell SOX2 marker induced by miR-10b, as opposed to PTEN with a mutated MRE. In addition, we knocked down PTEN in SKBR-3 overexpressing miR10b cells (Fig. 3G ) and in T-47D in which miR-10b was knocked down, and measured stem cell markers and mammospheres, respectively.
All the points showed were obtained by independent transfections using SYBR green RTqPCR, to ensure that there was a strong biological support. To address this issue, we performed additional experiments controlling better the transfections and using taqman qPCR probes. We reduced the variability, although, due to the differences in individual transfection experiments, we still observed some variability in our data.
4. Mammosphere/colony forming assay: It is not clearly described whether these are individual assays. A mammosphere assay is not described in the Materials and Methods section. It is inconsistent that sometimes colonies/spheres were counted and in other experiments dissociated and counted in single cell amounts. We produced new experiments using taqman assays, which improved the variability and produced plots which each gene separately.
All were triplicate biological replicates each performed three times (statements in
7. Fig 3B: the effect of miR-10b was shown by luciferase reporter assays using different 3'UTRs. In addition, the effects of miR-10b on endogenous transcripts and protein should be evaluated
We indeed evaluated endogenous transcripts and protein levels, as shown in Fig 3C and E. 8. (Fig. 3 C) In addition, as suggested, we also took advantage of two previously published cohorts of breast cancer patients and analyzed the correlation between the expression of PTEN and relapse-free survival (Fig. EV4A) or miR-10b and distant relapse-free survival (Fig. EV4B) , finding an statistical significative predictive value in both cohorts (p= for PTEN and p= for miR-10b) 9. Fig 3D: the effects on PTEN levels are rather marginal, especially in SKBR-3 and T47-D cells. Is there a biological relevance? Blots need to be quantified! Why are MDA-MB-231 cells not shown as well? In addition, it would support the findings, if MCF7 and MDA cells were shown before and after CSC-enrichment. Does PTEN loss also affect tumor growth in vivo in limiting dilutions and CD44 levels in a similar way than miR-10b elevation? The PTEN knockdown efficiency should be included in Fig. 3F . Fig. 3G) 10. Fig. 4 : Total AKT levels need to be included in the Western blots.
We provide densitometric analyses of the blots (Fig. 3E). Due to time restrains, we were unable to provide PTEN loss in vivo experiments. We added PTEN expression data from sorted MCF-7 and MDA-MB-231 cells (in the text, page 8). The PTEN knockdown efficiency was included (now
Total AKT levels were included.
Minor points: 1. Page 7: "We then selected 3 cell lines with high miR-10b expression and transiently transfected specific anti-miRs moieties." The analysis of different cell lines with respect to their miR-10b expression level is not shown. This is important to verify which cell lines have high and low miR10b expression levels, also with respect to the changes in miR-10b levels in the CSC-enriched fractions.
We corrected the text (page 7) specifying which cell lines were used and added their miR-10b expression levels (Fig. EV3C) :
"We performed experiments with either miR-10b overexpression or inhibition in four breast cancer cells lines and in MCF-7 CD44+ subpopulation. Twenty-four hours after a transient transfection of miR-10b-OE in MCF-7 and SKBR-3 cells, OCT4, SOX2, Vimentin and TWIST expression increased compared with the miR-Scr-OE control, which resembled the expression pattern of isolated CSCs (Fig. 2D). We then selected 2 cell lines with high miR-10b expression (T47-D and MDA-MB-231 cells, Fig. EV3C) and CD44+ MCF-7 cells and transiently transfected specific anti-miRs moieties."

Fig legend Fig 2D says TWIST and Snail, but it is not shown in the figure
We corrected this mistake.
Other miR-10b target candidates ( ASLX1, BAP1, GATA3) are mentioned but no analysis is presented. Were they not responding to manipulations of miR-10b?
We did not analyze these targets. We only tested HOXD10, PTEN and PI3KCA.
4. Fig 1E: it is not clearly indicated which cells are shown in each square. Why are the different expression levels not presented in an easier way, like in columns or in a table?
We added all the miRNAs that were regulated in both cell lines and clearly marked the cell lines used.
5. Fig. S2 : MDA: Also the genes from Fig 1F should be analyzed here. Legend does not fit with the figure.
We corrected the figure legend and produced additional MDA measurements which were added to Fig. 1F 3rd Editorial Decision 04 November 2015
Thank you for the submission of your revised manuscript to our editorial offices. We have now received feedback from the three original reviewers on it. While they appreciate the improvements over the previous version and, in principle, all support publication of the study in EMBO reports, referees 1 and 2 still have some concerns that would need to be addressed before your manuscript can be published.
While most of the concerns seem rather minor, referee 2 raises two major issues with the new data that would need to be addressed experimentally. I would like to give you the opportunity to perform the additional experiments as spelled out in this reviewers' comments; they are mostly additional controls and I do not expect them to be too difficult to address. ********************* REFEREE REPORTS Referee #1:
The authors have addressed most of my previous comments. Remaining issues:
1. Figure 2C : in addition to showing the tumor incidence at each cell dose and the p value, the authors need to calculate the frequency of CSCs for each group from the limiting dilution assays. 2. Figure 4A : the bands are hard to see. 3. The title of Figure 4 is "the effects of miR-10b on stemness are mediated by the PI3K pathway", but the assays (soft agar colony formation) shown in this figure are not stemness assays.
In this version of the manuscript, the authors have attempted to address most of the concerns that were previously expressed. Specifically, the authors now explain the rationale for exploring miR10b, and provide a more complete and detailed analysis of the entire panel of miRNAs deregulated in breast cancer.
Additionally, the authors have addressed the technical issues, providing the requested data set for miRNAs analysis as well as the entire panel of cell lines used in the manuscript. Further, they have fixed the discrepancy of rewires.
Although this manuscript has been improved, the data that is now included does not sufficiently address all the concerns regarding the results provided.
Major Concerns: 1) One of the major concerns of this manuscript is the role of AKT activation. The WBs (western blots) shown in Fig. 4 do not provide sufficient evidence; the bands are extremely weak, the total AKT shows a different expression in MCF7 miR-10b-OE as compared with Scr-OE, quantification is not provided, and the internal control is GAPDH in one blot and Actin in the other. Experiments with PTEN OE in a miR-10b-OE setting should restore the p-AKT level, however these data are not provided.
2) The data shown in PTEN re-expression are only relevant to stem cell markers (Fig. 3G) ; there are no data regarding AKT/p-AKT. AS it seems the major effect of miR-10b OE is related to stem cell marker deregulation and is not related to AKT activation as mentioned in the discussion and in the title.
Minor Concerns: 1) Figure 3 , Panel E: miR-10b overexpression (OE) is shown in MCF7 and SKBR-3, but miR-10b silencing is shown in MCF7 and T47-D. These data will be more convincing if the effects of OE and silencing were studied in the same cell lines.
2) Figure 3 , Panel H left The authors should provide relative expression of more than one stem cell marker (only SOX2 levels are provided)
3) Figure 3 , Panel G The effect of miR-10b-OE on OCT4/3 and SNAIL seems contradictory, the values did not change in a PTEN wild type setting as compared to a PTEN knock down setting, as the author mentions in the manuscript, the authors must provide a justification for this effect or, at least, provide a hypothetical explanation for these differential effects.
4) Fig EV2G
E-cadherin staining is provided as requested, and now the figure shows a staining of 2 samples, SKBR-3 WT and mir-10b OE, however the negative control for this experiment, miR-SCR-OE, is still not included.
5) Fig EV3
Legend, Panel A shows mir-10bOE samples and not SCR-OE, the authors need to provide these samples.
The authors substantially improved the manuscript by addition of a lot of new experiments and modifications. All my concerns were adequately addressed and I now recommend the manuscript for publication in EMBO Reports without any further revision. Referee #2:
We improved the western blot images and added the requested experiment using PTEN OE in a miR-10b-OE setting. 2) The data shown in PTEN re-expression are only relevant to stem cell markers (Fig. 3G) ; there are no data regarding AKT/p-AKT. AS it seems the major effect of miR-10b OE is related to stem cell marker deregulation and is not related to AKT activation as mentioned in the discussion and in the title. Minor Concerns: 1) Figure 3 , Panel E: miR-10b overexpression (OE) is shown in MCF7 and SKBR-3, but miR-10b silencing is shown in MCF7 and T47-D. These data will be more convincing if the effects of OE and silencing were studied in the same cell lines.
We selected these cell lines due to the basal levels of miR10b in each of them. We inhibited miR10b in those cells with higher levels and increased it in cells with low levels.
We repeated the experiments to try to validate more markers, adding an additional transfection control, to decrease variability. Nevertheless, after several new assays, we found only one statistically significative marker. We also improved the panel, as shown in Fig. 4I , by adding PTEN expression. Interestingly, the mutated PTEN version presented an increased expression, as expected by the mutation of the miR10b-binding site. We did not find statistical significative changes for other markers. This could be due to the forced levels of PTEN expression achieved by transfection, which could be saturating the system, as suggested by the p-AKT results in Fig. 4B lower panel, in which the levels of activated p-AKT are very low.
The panel shows the effects of PTEN knockdown on the stem genes expression, using the miRscr control cells (left panel) or the miR-10-OE cells (right panel). The expression was normalized using the values of the control dsiRNA (wild type PTEN), which are also shown as a bar. We indeed found a difference in the stem cell markers regulation between both cellular backgrounds. This could be due to a larger decrease in PTEN levels due to the additive effects of miR-10b and the PTEN shRNA, which in turn could regulate additional genes. This explanation was added to the paper.
4) Fig EV2G
We are sorry for the mistake. As reported for other experiments in the paper, we used miRscr cells as a control. We corrected the figure.
5) Fig EV3
We are sorry for the mistake. As reported for other experiments in the paper, we used miRscr cells as a control. We corrected the figure. I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports. Thank you for your contribution to our journal. ************************ REFEREE REPORT
The authors have adequately addressed all of our concerns. They have performed the experiments that were suggested in the previous review and they corrected all the Figures and Legends that were inaccurate.
The data included in the current version of the manuscript is much more consistent and overall the manuscript has been greatly improved. Is there an estimate of variation within each group of data? Is the variance similar between the groups that are being statistically compared? 6. To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile. e.g., Antibodypedia (see link list at top right), 1DegreeBio (see link list at top right).
7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination.
* for all hyperlinks, please see the table at the top right of the document 8. Report species, strain, gender, age of animals and genetic modification status where applicable. Please detail housing and husbandry conditions and the source of animals. 11. Identify the committee(s) approving the study protocol.
Yes.
Yes. Box plots were made to assess distribution and homogeneity of variances was evaluated with Levene´s test.
The range and/or standard deviation of each group were stimated.
In most of the experiments the variance was similiar between groups, but in those experiments were the variance was different, a non parametric test was used.
All the antibodies were described in the text, including the provider and catalog number. Material and Methods, page 12 to 15.
All cells were obtained from ATCC in 2014.
Athymic nu/nu female mice at eight weeks of age. Material and Methods, page 12 to 15.
All mouse experimentation was conducted in accordance with standard operating procedures approved by the University Committee on the Use and Care of Animals at the Metropolitan Autonomous University, Mexico. The nu/nu mice were purchased and maintained in UPAEL--UAM or INCan (Instituto Nacional de Cancerología) (DF, Mexico).
Instituto Nacional de Medicina Genomica Research Committe, Ethics in Research Committe
Three or four independent experiments were performed, each one for triplicate. The sample size was chosen by convenience No exclusion criteria was used. All the animals and samples were used in the analyses.
The researcher in charge of the animals did not have access to the anonymizing key, so it was a blinded study.
Subjetive randomization was used.
In vitro analyses were not blind.
The researcher in charge of the animals did not have access to the anonymizing key, so it was a blinded study. 
E--Human Subjects
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
In the pink boxes below, provide the page number(s) of the manuscript draft or figure legend(s) where the information can be located. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable).
B--Statistics and general methods
an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner. the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
